Dr. Lal Path Labs , a leading diagnostic services provider in India, has received an Assessment Order and Demand Notice from the Income Tax Department, the company disclosed in a recent filing. The order, pertaining to the financial year 2017-18, includes additions and disallowances amounting to ₹2.79 crore, resulting in an income tax demand of ₹2.43 crore.

Details of the Assessment Order

The company received the order on October 31, which outlines the following key points:

Company's Response

Dr. Lal PathLabs has stated that the tax demand does not have a material impact on its financials, operations, or other activities beyond the mentioned amount. The company is currently examining the order and plans to take appropriate steps, which may include filing an appeal against the assessment.

Investor Implications

While the tax demand is significant, it represents a relatively small fraction of the company's overall financial position. In its latest financial results, Dr. Lal PathLabs reported:

• Revenue of ₹731.00 crore
• EBITDA of ₹224.00 crore
• PAT of ₹152.00 crore

The tax demand of ₹2.43 crore is approximately 1.60% of the company's quarterly profit after tax, suggesting a limited immediate financial impact.

Looking Ahead

As Dr. Lal PathLabs navigates this tax issue, investors and stakeholders will be watching closely to see how the company addresses the demand and what impact, if any, it may have on future financial statements. The company's approach to resolving this matter could provide insights into its financial management and regulatory compliance strategies.

Dr. Lal PathLabs continues to maintain a strong market position in the diagnostic services sector, with a wide network of laboratories and patient service centers across India. The company's ability to manage regulatory challenges while maintaining its growth trajectory will be crucial for its long-term success in the competitive healthcare diagnostics market.

Dr. Lal PathLabs has successfully completed its bonus share allotment, with the Board of Directors approving the issuance through a circular resolution on December 22, 2025. The company allotted 8,37,75,510 fully paid-up bonus equity shares in the ratio of 1:1 to eligible shareholders.

Bonus Share Allotment Details

The bonus shares were allotted to shareholders whose names appeared in the Register of Members or List of Beneficial Owners as of the record date of December 19, 2025. Each eligible shareholder received one new fully paid-up equity share for every existing share held.

Enhanced Capital Structure

Following the bonus share allotment, the company's paid-up equity share capital has doubled from ₹83.78 crores to ₹167.55 crores. The total number of outstanding shares increased from 8.38 crores to 16.76 crores.

Previous Corporate Actions

Prior to this allotment, the company had announced a second interim dividend of ₹7.00 per equity share for the financial year 2025-26, with a record date of November 7, 2025. The company had also paid an earlier interim dividend of ₹6.00 per share in August 2025.

The bonus shares allotted rank pari-passu in all respects with the existing fully paid-up equity shares of the company. The allotment was funded from the company's Securities Premium Account, which stood at ₹1,247.85 million as per the audited financial statements for the year ended March 31, 2025.